Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients

Structure Therapeutics Inc. (NASDAQ:GPCR) was able to report positive results from its phase 2a study using its GLP-1R agonist GSBR-1290 for the treatment of patients with obesity in June 2024. This is an important outcome because it now leads to another milestone for investors to look forward to, which is the initiation of the 36-week phase 2b study using this drug to treat these patients in Q4 of 2024. The scope of this biotech though is its ability to achieve rapid weight loss in a short amount of time a ...